BC
HZNP

Broadfin Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Broadfin Capital’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-410,532
Closed -$8.04M – 59
2018
Q3 		$8.04M Sell
410,532
-929,043
-69% -$17.7M 1.18% 26
2018
Q2 		$22.2M Sell
1,339,575
-1,224,600
-48% -$18.7M 3.49% 9
2018
Q1 		$36.4M Sell
2,564,175
-453,846
-15% -$6.7M 5.67% 4
2017
Q4 		$44.1M Sell
3,018,021
-79,943
-3% -$1.12M 7.2% 2
2017
Q3 		$39.3M Sell
3,097,964
-962,883
-24% -$12.2M 5.81% 4
2017
Q2 		$48.2M Sell
4,060,847
-1,603,372
-28% -$19.9M 5.86% 4
2017
Q1 		$83.7M Sell
5,664,219
-295,600
-5% -$4.79M 10.14% 1
2016
Q4 		$96.4M Buy
5,959,819
+456,637
+8% +$8.28M 10.71% 1
2016
Q3 		$99.8M Sell
5,503,182
-1,360,666
-20% -$26.6M 8.94% 1
2016
Q2 		$113M Buy
6,863,848
+40,471
+0.6% +$655K 10.99% 2
2016
Q1 		$113M Sell
6,823,377
-1,307,933
-16% -$22.9M 10.92% 1
2015
Q4 		$176M Buy
8,131,310
+1,465,919
+22% +$28.5M 10.84% 1
2015
Q3 		$132M Buy
6,665,391
+1,849,584
+38% +$58.4M 7.35% 2
2015
Q2 		$167M Sell
4,815,807
-2,237,697
-32% -$68.3M 8.99% 2
2015
Q1 		$183M Sell
7,053,504
-1,864,471
-21% -$34.2M 14.27% 1
2014
Q4 		$115M Buy
8,917,975
+3,829,092
+75% +$47.9M 10% 1
2014
Q3 		$62.5M Buy
5,088,883
+735,669
+17% +$8.55M 6.55% 2
2014
Q2 		$68.9M Buy
4,353,214
+47,745
+1% +$681K 6.72% 2
2014
Q1 		$65.1M Buy
4,305,469
+48,000
+1% +$542K 6.31% 2
2013
Q4 		$32.4M Buy
4,257,469
+2,377,469
+126% +$12.8M 4.28% 6
2013
Q3 		$6.3M Buy
+1,880,000
New +$4.96M 1.12% 27

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Broadfin Capital's HZNP Position: Q4 2018 in Review

Broadfin Capital sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2018, closing a stake of 410,532 shares — an estimated $8.04M sold.

Broadfin Capital first reported a position in HZNP in Q3 2013 and held it in 21 quarters. The position peaked at $183M in Q1 2015. 239 funds tracked by Wall St. Rank hold HZNP as of Q4 2018.

  • Broadfin Capital reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2018 after selling out during the quarter.
  • Broadfin Capital sold 410,532 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2018, an estimated $8.04M.
  • Broadfin Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2013 and held it in 21 quarters.
  • Broadfin Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $183M in Q1 2015.
  • 239 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2018.

Based on Broadfin Capital's 13F filing for Q4 2018, filed 14 Feb 2019.